Was kommt nach den biologischen DMARDs?

• Literatur

• 1 Cohen SB, Tanaka Y, Mariette X. et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 2017. Epub vor Druck
• 2 Van Vollenhoven RF, Fleischmann R, Cohen S. et al. ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-519.
• 3 Singh JA, Hossain A, Tanjong Ghogomu E. et al. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database Syst Rev 2017. Epub vor Druck
• 4 Taylor PC, Keystone EC, van der Heijde D. et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med 2017; 376: 652-662.
• 5 Genovese MC, Kremer J, Zamani O. et al. Baricitinib in Patients with Refractory Rheumatoid Arthritis. N Engl J Med 2016; 374: 1243-1252.
• 6 Smolen JS, Kremer JM, Gaich CL. et al. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis 2016; 76: 694-700.